US equities |
MU $968.80 ▲+4.31% META $612.42 ▼-1.25% SPCX $144.01 ▼-3.08% TSLA $400.00 ▼-1.83% SNDK $1,360.00 ▲+4.23% NVDA $217.75 ▼-0.09% SKHY $160.52 ▲+10.43% GOOGL $323.56 ▲+0.93%
FinancialContent

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

0.8900 +0.0200 (+2.30%)
Delayed Quote Updated: 10:47 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tiziana Life Sciences Ltd - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
--News Direct-- 
Via News Direct
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
Tiziana Life Sciences reports six-month PET scan results for MS patients
--News Direct-- 
Via News Direct
Tiziana Life Sciences reports six-month PET scan results for MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
News headline image
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana to Announce Six-Month Human Safety and Biomarker Data at the ECTRIMS Annual Congress, Following-Up from Positive Outcomes Data Presented in June
--News Direct-- 
Via News Direct
News headline image
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June ↗
Tiziana (NASDAQ: TLSA) is following up with anticipated human data and announced the acceptance of a late-breaking poster at the 39th Congress of the Europea 
Via Benzinga
News headline image
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
--News Direct-- 
Via News Direct
News headline image
Cathie Wood Sells $25 Million In Tesla Stock As TSLA Flashes Aggressive Buy Signal ↗
Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday. 
Via Investor's Business Daily
News headline image
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update ↗
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
News headline image
Latest AI Quantum Computing News And Company Stock Performances YTD ↗
The global quantum computing market is expected to grow at a CAGR of 38.3% over the next 5 years which presents an incredible opportunity for investors so which AI quantum computing stocks are... 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients ↗
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab... 
Via Benzinga
News headline image
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Cathie Wood Dumps 170,000 Tesla Shares This Week As TSLA Falls Harder Than The S&P 500 ↗
Wood continued selling Tesla shares as TSLA forged a new buy point. 
Via Investor's Business Daily
Topics Stocks
News headline image
Tesla Cybertruck To Be Used For Oracle's Next-Gen Police Car ↗
Oracle Corp (NYSE: ORCL) co-founder and Executive Chairman Larry Ellison recently made a surprising reveal during his CloudWorld talk. 
Via Benzinga
News headline image
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light ↗
Tiziana Life Sciences Ltd. 
Via Benzinga
Tiziana Life Sciences' Alzheimer's treatment validated in new study
--News Direct-- 
Via News Direct
Tiziana Life Sciences' Alzheimer's treatment validated in new study
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
News headline image
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... 
Via Benzinga
News headline image
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision ↗
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >